| DC66452 |
Survodutide
Featured
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake. |
|
| DC66453 |
FOXO4-DRI
Featured
|
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53. FOXO4-DRI is a senolytic peptide that induces apoptosis of senescent cells. |
|
| DC66454 |
Melanotan I acetate
Featured
|
Melanotan I acetate is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I acetate is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I acetate can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I acetate can be used for sunlight-induced skin cancers research. |
|
| DC60599 |
G-5758
Featured
|
G-5758 is a potent, selective, and orally available IRE1α inhibitor with IC50 of 38 nM in XBP1s reporter assay. G-5758 demonstrates a robust PD response in the KMS-11 tumor xenograft model. |
|
| DC60600 |
PFI-7
Featured
|
PFI-7 is a potent, selective and cell-active chemical probe that antagonizes Pro/N-degron binding to human GID4 with Kd of 79 nM. PFI-7 will be a valuable research tool for investigating CTLH complex biology and facilitating development of targeted protein degradation strategies that highjack CTLH E3 ligase activity. |
|
| DC60601 |
GLP-1-MK-801
Featured
|
GLP-1-MK-801 is a GLP-1-directed NMDA receptor antagonist for targeting to achieve cell-specifc ionotropic receptor modulation and highlights the therapeutic potential of unimolecular mixed GLP-1 receptor agonism and NMDA receptor antagonism. |
|
| DC60602 |
Jun12682
Featured
|
Jun12682 is a SARS-CoV-2 papain-like protease (PLpro) inhibitor with Ki of 37.7 nM and displays EC50 of 1.1 μM in the FlipGFP PLpro assay, more than 20-fold improved from GRL0617 (EC50=22.4 μM). |
|
| DC66455 |
Stanolone
Featured
|
|
|
| DC60604 |
CDD-2807
Featured
|
CDD-2807 is a potent serine/threonine kinase 33 (STK33) inhibitor with Kd of 0.02 nM and IC50 of 9.2 nM, respectively. CDD-2807 shows >9-fold selectivity versus other kinases and demonstrates excellent metabolic stability with T1/2 >60 min in MLM and HLM. |
|
| DC60605 |
Lipid 119-23
Featured
|
Lipid 119-23 is an ionizable lipid for mRNA delivery. 119-23 LNP exhibits an enhanced capability to express functional mCre in several categories of immune cells, spanning the liver, spleen and lung. |
|
| DC60606 |
KL-50
Featured
|
KL-50 is a selective toxin toward tumors that lack the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which reverses the formation of O6-alkylguanine lesions. KL-50 is the first reported compound to overcome acquired temozolomide resistance while maintaining high selectivity for MGMT-cells. |
|
| DC60607 |
SL-25.1188
Featured
|
SL-25.1188 is a reversible MAO-B inhibitor with high brain uptake and slow plasma metabolism, making it a promising candidate for treating Alzheimer's dementia and aiding in smoking cessation. Its ability to modulate neurotransmitter levels in the brain positions it as a valuable therapeutic tool for addressing these challenging conditions. |
|
| DC66456 |
TLR7/8 agonist 1
Featured
|
TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. |
|
| DC66457 |
FAP-IN-2 (FAPI)
Featured
|
FAP-IN-2 is a 99mTc-labeled FAPI inhibitor designed for tumor imaging. It targets fibroblast activation protein (FAP) in the tumor microenvironment, enabling high-contrast SPECT imaging of FAP-expressing tumors. Its specificity, stability, and imaging capabilities make it a valuable tool for cancer diagnosis, staging, and research. Additionally, it has potential theragnostic applications in oncology. |
|
| DC66458 |
FAPI -14
Featured
|
|
|
| DC60608 |
SL25.1188 precursor
Featured
|
SL25.1188 Precursor is a key intermediate in the synthesis of SL25.1188, a reversible and selective MAO-B radioligand. The radiolabeled form, [¹¹C]SL25.1188, is a promising PET imaging agent for studying MAO-B in the brain, with applications in neurodegenerative disease research and drug development. Its reversible binding and high selectivity make it a valuable tool for understanding MAO-B's role in health and disease. |
|
| DC66459 |
NOTA-FAPI
Featured
|
NOTA-FAPI is a FAP-targeted imaging probe with excellent tumor detection efficacy and imaging quality. Its high specificity for FAP, stable radiolabeling, and ability to visualize the tumor stroma make it a promising tool for tumor diagnosis, staging, and treatment monitoring. NOTA-FAPI has significant potential for advancing cancer imaging and therapy, particularly in cancers with a prominent stromal component. |
|
| DC66460 |
FAPI-4
Featured
|
FAPI-4 is a potent FAP inhibitor with significant applications in cancer research and diagnostics. Its radiolabeled form, ⁶⁸Ga-FAPI-4, is a promising PET/CT imaging agent for visualizing FAP-expressing tumors with excellent tumor-to-background contrast. This makes it a valuable tool for cancer diagnosis, staging, treatment monitoring, and therapeutic development, particularly in cancers with a prominent stromal component. |
|
| DC66461 |
SH-FAPI-4
Featured
|
SH-FAPI-4 is a specific fibroblast activation protein inhibitor (FAPI) compound that belongs to the FAPI family of molecules. SH-FAPI-4 is expected to selectively accumulate in FAP-positive tumors and disrupt the functions of cancer-associated fibroblasts (CAFs) within the tumor microenvironment. By inhibiting FAP activity, this compound aims to potentially slow tumor growth, enhance the efficacy of other cancer treatments, and modulate the tumor microenvironment. |
|
| DC66462 |
HYINC-FAPI-4
Featured
|
HYINC-FAPI-4 is a 99mTc-labeled derivative of fibroblast activation protein inhibitor (FAPI), specifically designed for single-photon emission computed tomography (SPECT) imaging of tumors expressing fibroblast activation protein (FAP). FAP is a key marker in the tumor stroma, which plays a critical role in tumor growth, invasion, and metastasis. |
.gif)
|
| DC66463 |
FAPI-46-NOTA
Featured
|
NOTA-FAPI-46 is an analogue of FAPI-46 (MedKoo Cat#207189). NOTA-FAPI-46 is useful in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). NOTA-FAPI-46 can be used as a PET tracer for detection of diseases or disorders related to fibroblast activation protein. |
|
| DC66464 |
3BP-3940
Featured
|
3BP-3940 is a highly potent FAP-targeting peptide with significant potential in theranostics. Its ability to be coupled with diagnostic and therapeutic radionuclides makes it a versatile tool for tumor imaging, targeted therapy, and treatment monitoring. By focusing on the tumor stroma, 3BP-3940 offers a promising approach to improving cancer diagnosis and treatment, particularly for cancers with prominent stromal involvement. As research progresses, 3BP-3940 could play a key role in advancing precision oncology. |
|
| DC66465 |
Pentanedioate
Featured
|
Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies. |
|
| DC66467 |
F-PSMA 1007
Featured
|
|
|
| DC66468 |
NOTA-octreotide
Featured
|
NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients |
|
| DC66469 |
DOTA-NOC
Featured
|
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. |
|
| DC66470 |
KN-93 phosphate
Featured
|
KN-93 phosphate is a novel membrane-permeant synthetic inhibitor of purified neuronal CaMK-II, with Ki of 370 nM. |
|
| DC66471 |
4-chloro-1-benzothiophene-2-carboxylic acid
Featured
|
|
|
| DC66472 |
6-bromo-1,2-dimethyl-1H-benzo[d]imidazole
Featured
|
|
|
| DC66473 |
SI-80
Featured
|
|
|
